Corsair

Greffex’s platform has numerous applications for delivering vaccines, gene therapies, cancer treatments, and transplantation therapies.

Greffex Universal Vaccine Application

We have an advanced, universal vaccine platform that delivers unprecedented time-to-market, cost efficiency, efficacy and safety through the use of proprietary clean adenoviral vectors
• Pipeline of over 12 vaccines including SARS-CoV-2, H5N1, Universal Flu, MERS-CoV, Anthrax, Ebola , tetrava- lent Dengue, Zika and Lyme’s disease

Greffex’s Competitive Advantage

When you start with a better foundation, the end result is enhanced. Greffex’s foundation is a fully-deleted, helper virus-independent adenoviral vector used to introduce genetic sequences for any chosen array of pro- teins. This technology is patented. No one else has such a clean vector (100% clean) with such a large payload capacity (33kb).